Invitae is facing a class action alleging that its genetic data was illegally shared with Labcorp following Labcorp’s acquisition of Invitae assets in 2024. The complaint, filed in Illinois, claims that genetic test results were integrated into Labcorp’s data assets without prior patient consent, in violation of the Illinois Genetic Information Privacy Act. The plaintiffs—identified as Illinois resident Julie Wiess and her son B.W.—seek class certification and damages tied to willful or reckless and negligent violations. Labcorp declined to comment in the reporting. For the biotech and diagnostics sector, the litigation spotlights the governance and consent requirements that increasingly accompany data-driven genomic services and post-acquisition integrations.